Chemotherapy for androgen-independent prostate cancer.
Chemotherapy for androgen-independent prostate cancer.
复制标题
DOI：
10.1053/suro.2002.35052
复制
发表时间：
2002-08-01
期刊：
影响因子：
--
通讯作者：
Petrylak, Daniel P
中科院分区：
文献类型：
--
作者：
Petrylak, Daniel P
虽然转移性前列腺癌患者通常对雄激素消融有良好的初始反应，但对于激素进行性耐药的前列腺癌，几乎没有可用的选择，而且化疗后的生存期不超过9到12个月。联合应用强的松和米托蒽醌对骨痛有显著的缓解作用，但不能延长存活期。在体内，与紫杉烷紫杉醇或多西紫杉醇联合使用的磷酸雌二胺(EMP)产生的细胞毒性大于相加的细胞毒性，基于紫杉烷的治疗的I期和II期研究表明，与历史对照相比，激素难治性前列腺癌的存活率有所提高。多西紫杉醇作为单一药物和与EMP联合使用似乎具有相对较高的活性。考虑到潜在的心血管毒性，还需要进一步的研究来阐明EMP的最佳剂量。其与多西紫杉醇联合的第三阶段研究正在进行中。
While men with metastatic prostate cancer frequently show a good initial response to androgen ablation, few options have been available for progressive hormone-refractory prostate cancer, and survival following chemotherapy has not exceeded 9 to 12 months. The combination of prednisone and mitoxantrone has significant palliative effects on bone pain but does not extend survival. The combination of estramustine phosphate (EMP) with the taxanes paclitaxel or docetaxel produces greater than additive cytotoxicity in vivo, and phase I and II studies of taxane-based therapy demonstrate improved survival in hormone-refractory prostate cancer compared to historical controls. Docetaxel appears to have relatively high activity as a single agent and in combination with EMP. Further studies are needed to clarify the optimum dose of EMP, taking into account potential cardiovascular toxicity. Phase III studies of its combination with docetaxel are in progress.